COPD Market Forecast

Published by: Datamonitor

Published: Nov. 29, 2011 - 6 Pages


Table of Contents

OVERVIEW
Summary
OVERVIEW
This product contains COPD market and product forecasts for the seven major markets (the US, Japan, France, Germany, Italy, Spain, and the UK) over 2011 to 2020. It has been designed for delivery in an Excel data pack format, but for more detail about this disease area please see the accompanying Market and Product Forecasts: COPD (HC000218-002) PDF document and PowerPoint executive presentation.
The associated report and PowerPoint presentation can be found under Latest Research in the Knowledge Center, through the search function, or by contacting your sales representative.
Please select the data pack option from the download menu at the side of the page to access the model.
Introduction
Features and benefits
Highlights
Key questions answered in this report
Forecasting methodology
Disclaimer

Abstract

Introduction

New product launches for COPD across the seven major markets will override generic erosion and boost market value from $8.2bn in 2011 to $9.6bn by 2020, representing a positive 2011–20 CAGR of 1.8%. Datamonitor forecasts 14 new product launches in COPD over the next 10 years, altering class dynamics and fracturing a market currently dominated by a handful of therapies.

Features and benefits
  • Access Datamonitor’s patient based COPD market forecast for the seven major markets, with transparent methodology and clear assumptions.
  • See how each new product launch will impact the market, and where the strongest competition lies.
  • Gain insight into COPD market dynamics, and see where untapped market potential remains.
  • Understand how currently marketed products are vulnerable to competition in the COPD market, and which products are insulated against brand erosion.
Highlights

Datamonitor forecasts that sales for COPD will reach $8.2bn in 2011 in the seven major markets, growing to $9.6bn by 2020, representing a positive 2011–20 CAGR of 1.8%, large untapped potential remains. Datamonitor’s survey of 125 pulmonologists shows a low diagnosis rate and large untreated population, particularly among mild patients.Datamonitor estimates that in 2011 LAMA dominates the COPD market with 27.1% market share, owing to the wide use of Spiriva. By 2020 highly anticipated LABA/LAMAs are forecast to hold 26.2% of the market, with sales of $2.5bn. The LAMA class’s share will drop to 25.9%, with the class remaining popular among mild and moderate patients.Datamonitor estimates that in 2011 Spiriva and Advair together hold 64.4% of the COPD market. Generic erosion and 14 new product launches will result in a more fractured COPD market over the next 10 years. By 2020 Spiriva is forecast to remain the market leader, but its share will drop from 37% to 19%.

Your key questions answered
  • What impact will generic erosion of key brands have on the launch of novel pipeline products?
  • How will current market leaders be impacted by additional product launches and which products will resist brand erosion?
  • How are class dynamics changing in COPD and what will be the most important drug class in 2020?
  • How do dynamics in each of the seven major markets compare to each other and which factors have led to commercial success?
  • Where does untapped patient potential remain?


Get full details about this report >>
 
Learn more about this product


Price and delivery options
Search Inside Report

US: 800.298.5699

Int'l: +1.240.747.3093

 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 400,000 market research reports, company profiles and country profiles from over 720 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.